Vitamin D: Analytical Advances, Clinical Impact, and Ongoing Debates on Health Perspectives

Abstract

Background Vitamin D, acknowledged since the 1930s for its role in preventing rickets, gained additional prominence in relation to fragility fracture prevention in the late 1980s. From the early 2000s, connections between vitamin D deficiency and extra-skeletal pathologies emerged, alongside increased awareness of widespread deficits. This prompted crucial debates on optimal serum concentrations, expected to conclude when the outcomes of high-dose supplementation randomized controlled trials were available. Skepticism arose with inconclusive results from these trials. Content This review begins with an exploration of vitamin D metabolism, followed by a detailed description of the measurement of vitamin D metabolites and the crucial role of standardization. Subsequent sections focus on the association of vitamin D with bone health and explore the extra-skeletal effects. The review concludes with a comprehensive discussion on the definition of vitamin D status and its implications for supplementation. Summary Despite standardization efforts, assay variations and challenges still exist, especially in specific patient groups. Vitamin D supplementation has a significant impact on bone metabolism and optimal vitamin D status improves the efficacy of antiresorptive drugs such as bisphosphonates. The extra-skeletal effects of vitamin D remain debated, but may include potential benefits in conditions such as respiratory infections and cancer mortality, particularly in deficient individuals. The definition of vitamin D sufficiency is nuanced, especially when variations in population groups and analytical methods are taken into account. Despite ongoing debates and recent mega-trials tempering enthusiasm, vitamin D remains a complex and essential element in human health. Further research is needed to clarify its role in various health outcomes and guide supplementation strategies.

Vitamin D receptor gene polymorphisms and multiple myeloma: a meta-analysis

“…An increasing number of studies have reported that patients newly diagnosed with MM have low levels of vitamin D [ 2 ], and vitamin D deficiency is correlated with myeloma activity [ 3 ], the occurrence of peripheral neuropathy (PN) [ 4 , 5 ], and poorer outcomes [ 6 ]. Evidence from laboratory has shown that analogs of vitamin D inhibit the growth of the myeloma cell line NCI-H929 via cell cycle arrest and apoptosis [ 7 – 11 ], and vitamin D supplements have potential for improving cancer prognosis and outcome in deficient individuals [ 12 ].…”